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ABSTRACT  
Background 
Dementia must be diagnosed accurately and early in the disease course to allow 
pathology-specific treatments to be effective. Dementia with Lewy bodies (DLB) is 
often misdiagnosed as Alzheimer’s Disease (AD), especially at the prodromal stage.  
 
Objective 
To compare the clinical and neuropsychological profiles of Mild Cognitive Impairment 
(MCI) patients who, at follow-up, progressed to AD (AD-MCI) or DLB (DLB-MCI) or 
remained MCI.  
 
Methods 
A longitudinal study that used an unselected sample from a memory clinic database. 
A total of 1,848 new patients were seen at the memory clinic between 1994 - 2015. 
Of these, 560 patients (30%) had an initial diagnosis of MCI and were considered for 
the study. Inclusion criteria were patients who had a diagnosis of MCI at initial 
assessment and a minimum of 12 months’ follow-up.  
 
Results 
Of the 429 MCI patients with follow-up data, 164 (38%) remained MCI, 107 (25%) 
progressed to AD, and 21 (5%) progressed to DLB. The remainder progressed to 
alternative diagnoses. At baseline, DLB-MCI patients performed significantly worse 
on visuospatial function and letter fluency tests than both AD-MCI and stable-MCI 
groups, and better on episodic memory tests than the AD-MCI group. At baseline 
DLB-MCI patients had a significantly higher mean UPDRS score and were more 
likely to have REM sleep behavior disorder and fluctuating cognition.  
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Conclusion 
DLB-MCI patients have a specific cognitive and neuropsychiatric profile which should 
alert clinicians to the possibility of prodromal DLB. This is relevant when considered 
in the context of early disease-specific therapy.  
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Introduction 
Dementia with Lewy bodies (DLB) is often overlooked and misdiagnosed as 
Alzheimer’s Disease (AD) due to overlap in clinical presentation [1,2]. Both DLB and 
AD are preceded by a prodromal period, generally denoted Mild Cognitive 
Impairment (MCI). It is generally acknowledged that pathology-specific treatments 
will need to target disease during the prodromal period. Therefore, it is important to 
identify patients during this phase. There is an extensive literature on the prodromal 
phase of AD, but limited literature on prodromal DLB.  
 
Patients with fully manifest DLB have a characteristic neuropsychological and 
neuropsychiatric profile which is distinct from patients with AD [3-6]. There is 
emerging evidence that even at the stage of MCI, DLB and AD patients have 
different neuropsychological profiles [7]. In a few early studies, patients with 
prodromal DLB more frequently exhibited fronto-executive, visuospatial and 
attentional deficits compared to those with prodromal AD. Prodromal AD patients 
more frequently had a prominent episodic memory deficit, which was present in only 
a minority of prodromal DLB patients [7]. 
 
Fluctuations in cognition, spontaneous parkinsonism, and REM sleep behaviour 
disorder (RBD) were more frequently observed in prodromal DLB compared to 
prodromal AD in some studies [8]. However, the literature is less consistent 
regarding the core feature of visual hallucinations (VH) [7]. 
 
The aim of the present study was to replicate the early findings in a large sample of 
patients from a non-academic setting. We therefore aimed to determine whether 
there are differences in the neuropsychological profile and clinical features of 
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patients with prodromal DLB compared to prodromal AD and stable-MCI in an 
unselected sample of MCI cases. 
 
Materials and Methods 
Study design 
The present study was a retrospective, longitudinal, observational study that used an 
unselected sample to test the hypothesis that patients with prodromal DLB will have 
a different cognitive and neuropsychiatric profile compared to patients with 
prodromal AD and stable-MCI.  
 
Setting 
The data used for the present study came from a Memory Clinic database. The 
Memory Clinic is part of the Old Age Psychiatry service in Essex, UK and provides 
specialized multidisciplinary assessments with emphasis on screening, early 
diagnosis and follow-up of patients at high risk of developing dementia. The clinic is 
part of the National Health Service, and it is based in a general hospital and covers 
inner city, suburban and rural areas with variable socioeconomic status. There is 
limited private provision of psychiatric diagnostic services in the UK and therefore the 
clinic benefits from near complete coverage of the local population. 
 
Participants 
A total of 1,847 new patients were seen at the Memory Clinic between 1994 and 
2015. Of these, 559 patients (30.3%) had an initial diagnosis of MCI and were 
therefore considered for the present study (see figure 1). Inclusion criteria were 
patients who had a diagnosis of MCI at initial assessment with a minimum of 12 
months of follow-up.  
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All patients referred to the Memory Clinic underwent a comprehensive medical and 
psychiatric assessment and a physical examination by a doctor. Comprehensive 
neuropsychometric testing was performed by a psychologist. Following this, a 
multidisciplinary team of old-age psychiatrists, clinical psychologists and a memory 
clinic nurse assigned a consensus diagnosis according to published criteria [9-11]. At 
each yearly follow-up, the same process was repeated again assigning a consensus 
diagnosis which was recorded on the clinical database. 
 
Ethical Review 
The present study was reviewed and received approval from London – South East 
Research Ethics Committee with reference number 15/LO/1752. 
 
Data collected at baseline and yearly intervals 
Data collected for each patient at baseline included age, gender, years of education, 
medical and psychiatric history, mental state examination and physical examination 
(including full neurological examination). Schedules performed included the Clinical 
Dementia Rating (CDR) [12], and Modified Hachinski score (at baseline only) [13]. 
The presence of DLB features was assessed and recorded at each visit, with support 
from the Clinician Assessment of Fluctuation Scale [14], Mayo Sleep Questionnaire 
[15], and the Unified Parkinson Disease Rating Scale part III (UPDRS) [16]. Patients 
with significant depressive or anxiety symptoms fulfilling ICD-10 diagnosis of a mood 
disorder or a neurotic, stress-related and somatoform disorder were excluded. In the 
very early stages of the study, before some of the above scales were available, a 
locally devised checklist was used to capture sleep disorders and fluctuations. 
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Cognitive testing included Mini-Mental State Examination (MMSE) [17], the 
CAMCOG-R [18], Wechsler Memory Scale (third edition abbreviated) Logical 
Memory Test (WMS LMT) [19], and tests of executive function (Trail Making Tests A 
and B, category and letter fluency (FAS)). Additionally, a 10-item word recall task 
was used where scores reflect the mean of 3 tries to recall the list [20]. 
 
Subdomains of the CAMCOG-R (maximum scores) are: Orientation (10), Language 
comprehension (9), Language expression (21), Remote memory (6), Recent memory 
(4), New learning (17), Attention/calculation (9), Praxis (12), Abstract thinking (8) and 
Perception (9). The CAMCOG-R includes a task of drawing a clock showing a 
specific time. On the CAMCOG-R this is part of the praxis subdomain and is scored 
out of 3. However the ACE-R [21] scoring rubric was applied to this item and was 
scored out of 5. At each follow-up, all schedules and cognitive testing were repeated 
with the exception of modified Hachinski score. Any additional medical or surgical 
history was also recorded. 
 
At baseline, all patients had a dementia blood screen, and structural imaging 
performed. Imaging was preferentially MRI but CT was performed where MRI was 
contraindicated or where the patient was unable to tolerate MRI. Imaging reports 
included Fazekas score for vascular pathology. At follow-up, imaging was only 
repeated where there was a specific clinical indication. 
 
For the diagnosis of MCI, the Petersen et al criteria were used [11]. Patients with 
MCI were divided into amnestic and non-amnestic categories based on their 
performance on the WMS LMT [19]. At follow-up, established criteria were used for 
the diagnosis of clinically probable AD and DLB [9,10] by a multidisciplinary 
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consensus. Other diagnostic groups were excluded from the study, including patients 
with subjective cognitive impairment (subjective cognitive complaints but 
performance not below 1.5 standard deviations of the norm expected for age on 
WMS LMT), Vascular dementia [Roman GC, Tatemichi TK, Erkinjuntti T, Cummings 
JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, et al. 
Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-
AIREN International Workshop.Neurology 1993 Feb;43(2):250-60.], Parkinson’s 
disease dementia [Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for 
dementia associated with Parkinson’s disease. Mov Disord 2007; 22: 1689–707.] 
and Frontotemporal dementia [J Neurol Neurosurg Psychiatry. 1994 Apr; 57(4): 416–
418. Clinical and neuropathological criteria for frontotemporal dementia. The Lund 
and Manchester Groups; Neurology. 1998 Dec;51(6):1546-54. 
Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. 
Neary D1, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, 
Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF.]. 
 
 
Statistical Analysis 
Statistical analyses were carried out using IBM SPSS version 19. We calculated 
baseline group characteristics for three groups of patients with MCI: those who 
remained stable (stable-MCI), those who declined to DLB (DLB-MCI) and those who 
declined to AD (AD-MCI). Data for continuous variables were not normally distributed 
therefore these were compared using Kruskal-Wallis tests. Mann-Whitney U-tests 
(two-tailed) were used to make pairwise comparisons only where the ANOVA was 
significant at p<.05. Chi-square or Fisher’s exact tests were used to determine 
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whether there were group differences on categorical variables. Where the 3-group 
test had a p<.05, pairwise analyses were performed.  
 
Results 
Of the 1,848 patients seen at the memory clinic, 560 patients had an initial diagnosis 
of MCI, 496 had AD (no significant vascular pathology on MRI or CT) or AD with 
cerebrovascular disease (presence of small vessel ischemia on MRI or CT, Fazekas 
score 1-2 [22]), 192 had Subjective Cognitive Impairment [23], 141 had other 
neurological disorders, 130 had vascular dementia, 115 had a psychiatric disorder, 
67 had DLB, 43 had Fronto-temporal dementia, 30 had dementia unspecified, 15 
had alcohol related cognitive decline, 11 had Parkinson’s Disease with dementia and 
48 had other diagnoses. 
 
Of the 559 MCI patients, 428 had a minimum of one year follow-up. One hundred 
and sixty-four remained MCI (stable-MCI) while 107 progressed to AD and 21 to DLB 
at last follow-up. For the whole cohort, the mean follow-up was 2.8 years. One 
hundred and twenty-five patients were excluded due to alternative diagnoses at 
follow-up and 11 were excluded due to missing data (see Figure 1). 
 
The demographic details of the three groups are listed in Table 1. The stable-MCI 
patients were younger and this reached statistical significance versus patients who 
converted to AD. As expected, UPDRS score was higher in the MCI patients who 
converted to DLB compared to patients who converted to AD as well as patients with 
stable-MCI. There was a greater proportion of males in the DLB-MCI group relative 
to the other two groups. The patients with stable-MCI had longer follow-up as they 
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continued to be followed-up clinically whereas the patients progressing to dementia 
were referred to treatment clinics.  
 
There was a greater proportion of patients with amnestic MCI subtype in the AD-MCI 
group relative to the other two groups. There was a higher frequency of visual 
hallucinations (VH), fluctuating cognition and REM sleep behaviour disorder (RBD) in 
the DLB-MCI group but this only reached significance for fluctuating cognition and 
RBD (see Table 1). 
 
DLB-MCI patients performed significantly worse than AD-MCI patients and stable-
MCI patients on letter fluency and the clock drawing test. DLB-MCI patients 
performed significantly better than AD-MCI patients on the new learning subscale of 
CAMCOG-R.  For a full list of results on cognitive testing, see Tables 2 and 3. 
 
Scores for patients at time of conversion to dementia or last follow-up are shown in 
Tables 4-6. Three patients with a DLB diagnosis had dopamine transporter SPECT 
imaging (all 3 cases had an abnormal scan, reduced uptake). No autopsies were 
available. During post-diagnostic follow-up, DLB patients developed further typical 
features which increased the certainty of the DLB diagnosis (95% had parkinsonism, 
71% had visual hallucinations, 57% had fluctuations and 38% had RBD). 
 
Discussion 
In this large cohort, we found that already at the stage of MCI, there are clear 
differences in clinical features between patients who developed DLB, patients who 
progressed to AD, and those who remained stable. There are also clear differences 
on a number of cognitive tests. MCI patients who progressed to DLB were 
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significantly more likely to have parkinsonism, fluctuating cognition and REM sleep 
behaviour disorder (RBD) even at this early stage. They also had more frequent 
visual hallucinations (VH), although this was only a trend. On cognitive testing, 
patients that later progressed to DLB performed worse at baseline on letter fluency 
and on a visuospatial task compared to patients that progressed to AD. 
 
Overall, our results are in keeping with the findings of previous studies. Our finding 
that patients with prodromal DLB are more likely to have RBD, cognitive fluctuations 
or parkinsonism is in keeping with the existing literature [7,8,24,25]. Some studies 
have found VH to be more common, but in our study this was only a trend at the 
stage of MCI.  
 
This study strengthens the concept of prodromal DLB [26] and suggests that the 
core and suggestive features of DLB can be present a number of years before the 
manifestation of significant cognitive decline and functional impairment. The 
presence of these features in MCI patients should alert clinicians that this could be 
the early stages of DLB. Performing more in-depth cognitive assessment can also 
add support to the diagnosis of prodromal DLB. We have found impairment in 
visuospatial ability and this is consistent with the findings of previous studies 
[7,8,24,25]. We have also found a significant difference in letter fluency relative to 
prodromal AD or stable-MCI which is consistent with the existing literature with the 
exception of one study [25] which did not find a difference. 
 
The diagnosis of prodromal DLB is important. Any successful disease modifying 
treatment for DLB will have to be pathology-specific and will need to be introduced at 
the earliest possible stage of the disease course. This is also relevant to AD trials 
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which depend on the study cohort having specific AD pathology. Contamination of 
prodromal AD cohorts by prodromal DLB could be a major obstacle to success. 
 
The strengths of this study include that it is the largest cohort of its kind in Europe 
and the second largest worldwide [7]. Furthermore, it reports on an unselected 
incidence cohort from a secondary care service serving a local population with a 
clear catchment area and very limited alternative private provision. All patients 
underwent an identical comprehensive assessment at each follow-up and only a very 
small number of cases had missing data. All diagnoses were made by consensus in 
a multidisciplinary team and patients had a good length of follow-up. 
 
This study had some limitations. Diagnosis was made according to the present 
diagnostic criteria based on clinical features only without the support of dopamine 
transporter scan in the majority of cases. No cases had polysomnography. The 
observed differences are at a group level and do not allow clinicians to accurately 
predict the outcome for individual patients. This will most probably require additional 
biomarkers to support the clinical diagnosis of prodromal DLB. Another limitation is 
the lack of neuropathological confirmation of diagnosis which will require a long-term 
follow-up. Lastly, only a small proportion of the initial MCI cohort converted to DLB 
although this is consistent with the lower incidence of DLB compared to AD. 
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Table 1 Demographic and clinical data for the groups.  
 
Abbreviations: MCI=mild cognitive impairment; DLB=dementia with Lewy bodies; 
AD=Alzheimer’s disease; AMCI=amnestic MCI; NAMCI=non-amnestic MCI;  
 
DLB-MCI 
(n=21) 
AD-MCI 
(n=107) 
Stable-MCI 
(n=164) 
P 
Value 
Gender 18M: 3F a,b 54M: 53F a 77M: 87F b <.01 
Age at first visit (years) 75.1 (6.2) 75.9 (7.1) a 71.9 (9.6) a <.01 
Education (years)# 11.4 (3.4) 11.0 (2.3) 11.0 (2.3) .81 
Estimated duration of 
symptoms (yrs)^ 
1.8 (1.1) 2.2 (2.0) 2.4 (2.7) .65 
Length of follow-up (yrs)∆ 2.2 (1-8) 1.8 (1 -14) 2.4 (1-14) .13 
MCI subtype 
52% AMCI: 
48% NAMCI 
69% AMCI:  
31% NAMCI a 
46% AMCI: 
54% NAMCI a 
<.01 
IADL* 8.2 (3.4) 8.1 (2.8) 8.1 (2.7) .69 
Modified Hachinski 
Ischemic Score 
1.3 (1.5) 1.2 (1.6) 1.6 (1.9) .50 
UPDRS 8.5 (8.6) a, b 2.9 (5.1) a 3.9 (5.3) b <.01 
Parkinsonism (%) 57.1 a, b 11.2 a 16.5 b <.01 
Visual Hallucinations (%) 9.5 0.9 2.4 .06 
Fluctuating Cognition (%) 14.3 a, b 1.9 a 2.4 b <.01 
RBD (%) 19.0 a, b 0.9 a 1.2 b <.01 
Family history of AD (%) 9.5 a 31.1 a, b 20.5 b <.05 
Family history of PD (%) 14.3 5.7 4.8 .22 
 21 
 
UPDRS=unified Parkinson’s disease rating scale; IADL=instrumental activities of 
daily living; RBD=rapid eye movement sleep behaviour disorder. 
Values for continuous variables are mean (standard deviation). ∆For length of follow-
up, values are median (range). Categorical variables are compared with Chi Square; 
Continuous variables are compared with Kruskal-Wallis for 3-way group 
comparisons and Mann-Whitney U test for 2-way group comparisons. Letters a and 
b are used to denote pairs that differ at p<.05. #1 MCI-DLB case, 3 MCI-AD and 6 
stable-MCI cases had missing data for years education. ^1 MCI-AD and 2 stable-
MCI cases had missing data for duration of cognitive difficulties. *4 MCI-AD Cases 
and 25 stable-MCI cases had missing data for IADL.  
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Table 2 Neuropsychological test scores for the groups 
 
Abbreviations: MCI=mild cognitive impairment; DLB=dementia with Lewy bodies; 
AD=Alzheimer’s disease; MMSE=mini mental state examination; LMT=logical 
memory test; TMT=trail making test. Values are mean (standard deviation). 
Variables are compared with Kruskal-Wallis for 3-way group comparisons and Mann-
Whitney U test for 2-way group comparisons. Letters a and b are used to denote 
pairs that differ at p<.05.  #1 DLB-MCI case, 1 AD-MCI case and 1 stable-MCI case 
had missing data for word recall. ǂ2 stable-MCI cases had missing data for TMT-A 
due to non-completion. ∆9 DLB-MCI cases, 27 AD-MCI cases and 38 stable-MCI 
cases had missing data for TMT-B due to non-completion. *1 DLB-MCI case, 9 AD-
MCI cases and 15 stable-MCI cases had missing data for Clock drawing test. 
 Table 3 Cambridge Cognitive Examination-Revised test scores for the groups.   
 
DLB-MCI 
(n=21) 
AD-MCI 
(n=107) 
Stable-MCI 
(n=164) 
P 
value 
MMSE 25.8 (3.7) 25.9 (2.4) 26.4 (2.4) .18 
Word recall# 5.3 (1.2) 5.0 (1.3) a 5.5 (1.3) a <.01 
LMT Immediate 
%ile 
30.5 (31.0) 26.2 (25.6) 30.8 (30.2) .64 
LMT Delayed %ile 23.9 (26.4) 15.5 (22.7) a 27.3 (28.6) a <.01 
Letter Fluency 27.2 (11.7) a, b 34.8 (12.0) a 32.7 (12.3) b .02 
Category Fluency 14.4 (6.1) 15.2 (5.0) 15.4 (4.6) .55 
TMT-Aǂ 59.5 (23.9) a 55.6 (27.2) b 48.4 (19.9) a, b .01 
TMT-B∆ 146.8 (91.2) 115.2 (52.3) 111.0  (62.7) .22 
Clock drawing 
test*  
3.8 (0.9) a, b 4.2 (1.0) a 4.3 (0.9) b .02 
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DLB-MCI 
(n=21) 
AD-MCI 
(n=107) 
Stable-MCI 
(n=164) 
P 
value 
CAMCOG-R total 88.4 (6.3) 87.0 (6.1) a 89.3 (6.3) a .01 
Orientation 9.2 (1.0) 9.0 (1.2) a 9.4 (0.9) a <.01 
Language 
comprehension  
8.5 (0.7) 8.6 (0.8) 8.5 (0.7) .41 
Language expression 17.6 (2.0) 17.5 (2.3) 17.8 (1.7) .24 
Remote memory 4.8 (1.3) 5.0 (1.1) a 4.7 (1.4) a <.05 
Recent memory 3.4 (0.7) 3.3 (0.8) a 3.5 (0.7) a .05 
New learning 11.4 (2.8) a 10.2 (2.9) a, b 12.1 (2.4) b <.01 
Attention 7.7 (1.5) 8.0 (1.2) 7.6 (1.7) .30 
Praxis 11.1 (1.1) 11.0 (1.1) 11.1 (1.0) .26 
Abstract thinking 6.2 (1.5) 6.1 (1.5) 6.3 (1.5) .66 
Perception 8.3 (1.0) 8.2 (1.1) 8.4 (0.9) .34 
 
Abbreviations: MCI=mild cognitive impairment; DLB=dementia with Lewy bodies; 
AD=Alzheimer’s disease; CAMCOG-R=Cambridge Cognitive Examination-Revised. 
Values are mean (standard deviation).  Variables are compared with Kruskal-Wallis 
for 3-way group comparisons and Mann-Whitney U test for 2-way group 
comparisons. Letters a and b are used to denote pairs that differ at p<.05  
 
 
 
 
 
 
Table 4 Demographic and clinical data for the groups at follow-up 
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Abbreviations: MCI=mild cognitive impairment; DLB=dementia with Lewy bodies; 
AD=Alzheimer’s disease; IADL=instrumental activities of daily living; UPDRS=unified 
Parkinson’s disease rating scale; RBD=rapid eye movement sleep behaviour 
disorder. Values for continuous variables are mean (standard deviation). Categorical 
variables are compared with Chi Square; Continuous variables are compared with 
Kruskal-Wallis for 3-way group comparisons and Mann-Whitney U test for 2-way 
group comparisons. Letters a, b and c are used to denote pairs that differ at p<.05.  
 
 
 
 
 
 
 
 
 
Table 5 Neuropsychological test scores for the groups at follow-up 
 DLB (n=21) AD (n=107) 
Stable-MCI 
(n=164) 
P 
Value 
IADL 10.5 (4.9) 12.0 (5.5) a 9.1 (3.2) a <.01 
UPDRS 13.4 (11.7) a, b 3.8 (6.0) a 4.0 (5.9) b <.01 
Parkinsonism (%) 90.5 a, b 10.3 a, c 20.1 b, c <.01 
Visual Hallucinations (%) 33.3 a, b 2.8 a 1.2 b <.01 
Fluctuating Cognition (%) 19.0 a 4.7 3.0 a .02 
RBD (%) 23.8 a 5.6  4.3 a .02 
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Abbreviations: MCI=mild cognitive impairment; DLB=dementia with Lewy bodies; 
AD=Alzheimer’s disease; MMSE=mini mental state examination; LMT=logical 
memory test; TMT=trail making test. Values are mean (standard deviation). 
Variables are compared with Kruskal-Wallis for 3-way group comparisons and Mann-
Whitney U test for 2-way group comparisons. Letters a and b are used to denote 
pairs that differ at p<.05. ∆12 DLB cases, 58 AD cases and 52 stable-MCI cases had 
missing data for TMT-B due to non-completion. 
 
 
 
 
Table 6 Cambridge Cognitive Examination-Revised test scores for the groups at 
follow-up 
 DLB (n=21) AD (n=107) 
Stable-MCI 
(n=164) 
P 
value 
MMSE 23.7 (4.1) a 22.6 (3.4) b 25.9 (2.8) a, b <.01 
Word recall 4.5 (1.3) a 3.9 (1.1) b 5.5 (1.4) a, b <.01 
LMT Immediate 
%ile 
21.7 (24.4) 13.6 (17.4) a 34.9 (29.4) a <.01 
LMT Delayed %ile 28.4 (25.7) a 7.3 (12.8) a, b 34.3 (31.4) b <.01 
Letter Fluency 22.4 (11.2) a, b 29.8 (12.8) a 31.0 (11.8) b .02 
Category Fluency 12.1 (5.3) a 12.6 (4.6) b 15.3 (5.2) a, b <.01 
TMT-A 73.1 (33.8) a 60.1 (29.2) b 53.3 (25.7) a, b .01 
TMT-B∆ 151.9 (81.4) 123.4 (66.2)  108.4 (56.4) .10 
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 DLB (n=21) AD (n=107) 
Stable-MCI 
(n=164) 
P 
value 
CAMCOG-R total 80.9 (10.2) a 77.4 (7.8) b 88.3 (7.0) a, b <.01 
Orientation 8.6 (1.6) a 7.5 (1.8) a, b 9.0 (1.2) b <.01 
Language comprehension  8.2 (1.0) a 8.2 (0.8) b 8.6 (0.7) a, b <.01 
Language expression 16.6 (2.0) a 16.5 (2.1) b 17.7 (1.6) a, b <.01 
Remote memory 4.9 (1.5) 4.4 (1.3) 4.6 (1.3) .23 
Recent memory 2.8 (1.2) a 2.5 (1.1) b 3.4 (0.9) a, b <.01 
New learning 10.8 (3.2) a 7.7 (3.1) a, b 12.0 (2.9) b <.01 
Attention 7.0 (2.1) 6.5 (2.1) a 7.5 (1.6) a <.01 
Praxis 10.4 (1.5) 10.5 (1.5)  10.9 (1.1)  .08 
Abstract thinking 4.7 (1.8) a 5.5 (1.9) b 6.2 (1.6) a, b <.01 
Perception 7.2 (1.9) a 7.9 (1.1) b 8.2 (1.2) a, b <.01 
 
Abbreviations: MCI=mild cognitive impairment; DLB=dementia with Lewy bodies; 
AD=Alzheimer’s disease; CAMCOG-R=Cambridge Cognitive Examination-Revised 
Values are mean (standard deviation).  Variables are compared with Kruskal-Wallis 
for 3-way group comparisons and Mann-Whitney U test for 2-way group 
comparisons. Letters a and b are used to denote pairs that differ at p<.05  
 
 
 
 
Figure 1 Flowchart showing diagnoses at baseline and follow-up 
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Abbreviations: DLB=dementia with Lewy bodies; AD=Alzheimer’s disease; MCI=mild 
cognitive impairment. *126 patients had alternative diagnosis at last follow-up: 
Subjective Cognitive Impairment=50; Vascular Dementia=37; Psychiatric 
disorders=6; Frontotemporal Dementia=5; Unspecified Dementia=5; Other 
neurological disorders=7; Other=16. 
